Who
Alise Reicin
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Tectonic Therapeutic; Director, Immatics; Director, Sana Biotechnology; Director, Leverage Shares 2X Long FIX Daily ETF; Pres., Global Clinical Dev., Celgene Corp /de/.
In numbers
- Trades disclosed
- 60
- Buys
- 2
- Sells
- 0
- Bought
- $211K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 1 Nov 2018
- Last trade
- 25 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Sep 2026filed 2 Oct 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $37K1,545 at $23.67 | filing |
| 3 Sep 2026filed 8 Sep 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,250 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,250 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $28K924 at $30.34 | filing |
| 20 Jun 2026filed 23 Jun 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $28K924 at $30.34 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IMTX Immaticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | IMTX Immaticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —76,500 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,250 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic Therapeuticoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,250 at $0.00 | filing |
| 4 Mar 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code A | —76,500 at $0.00 | filing |
| 11 Feb 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $53K2,500 at $21.10 | filing |
| 11 Feb 2026filed 5 Mar 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $53K2,500 at $21.10 | filing |
| 11 Feb 2026filed 12 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $53K2,500 at $21.10 | filing |
| 11 Feb 2026filed 12 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Bought | $53K2,500 at $21.10 | filing |
| 4 Feb 2026filed 10 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $95K4,104 at $23.22 | filing |
| 4 Feb 2026filed 10 Feb 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code F | $95K4,104 at $23.22 | filing |
| 31 Dec 2025filed 5 Jan 2026 | TECX Tectonic TherapeuticBiotechnology | SEC FORM 4 Code M | $26K10,966 at $2.38 | filing |
News
No headline names them, or the companies they trade most, lately.